[go: up one dir, main page]

FR16C0042I2 - DERIVATIVES OF HETEROCYCLIC COMPOUNDS AND DRUGS - Google Patents

DERIVATIVES OF HETEROCYCLIC COMPOUNDS AND DRUGS

Info

Publication number
FR16C0042I2
FR16C0042I2 FR16C0042C FR16C0042C FR16C0042I2 FR 16C0042 I2 FR16C0042 I2 FR 16C0042I2 FR 16C0042 C FR16C0042 C FR 16C0042C FR 16C0042 C FR16C0042 C FR 16C0042C FR 16C0042 I2 FR16C0042 I2 FR 16C0042I2
Authority
FR
France
Prior art keywords
drugs
derivatives
heterocyclic compounds
heterocyclic
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR16C0042C
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nippon Shinyaku Co Ltd
Original Assignee
Nippon Shinyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=18978246&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR16C0042(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nippon Shinyaku Co Ltd filed Critical Nippon Shinyaku Co Ltd
Publication of FR16C0042I1 publication Critical patent/FR16C0042I1/en
Application granted granted Critical
Publication of FR16C0042I2 publication Critical patent/FR16C0042I2/en
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/18—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
FR16C0042C 2001-04-26 2016-10-24 DERIVATIVES OF HETEROCYCLIC COMPOUNDS AND DRUGS Active FR16C0042I2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001129765 2001-04-26
PCT/JP2002/004118 WO2002088084A1 (en) 2001-04-26 2002-04-25 Heterocyclic compound derivatives and medicines

Publications (2)

Publication Number Publication Date
FR16C0042I1 FR16C0042I1 (en) 2016-12-09
FR16C0042I2 true FR16C0042I2 (en) 2017-03-17

Family

ID=18978246

Family Applications (1)

Application Number Title Priority Date Filing Date
FR16C0042C Active FR16C0042I2 (en) 2001-04-26 2016-10-24 DERIVATIVES OF HETEROCYCLIC COMPOUNDS AND DRUGS

Country Status (19)

Country Link
US (1) US7205302B2 (en)
EP (1) EP1400518B1 (en)
JP (1) JP4479152B2 (en)
KR (1) KR100921760B1 (en)
CN (1) CN1301973C (en)
BE (1) BE2016C051I2 (en)
BR (1) BRPI0209249B8 (en)
CA (1) CA2445344C (en)
DE (1) DE60217674T2 (en)
DK (1) DK1400518T3 (en)
ES (1) ES2276931T3 (en)
FR (1) FR16C0042I2 (en)
LU (1) LU93266I2 (en)
MX (1) MXPA03009800A (en)
NL (1) NL300836I2 (en)
PT (1) PT1400518E (en)
RU (1) RU2283835C3 (en)
TW (1) TWI316055B (en)
WO (1) WO2002088084A1 (en)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7326706B2 (en) 2003-08-15 2008-02-05 Bristol-Myers Squibb Company Pyrazine modulators of cannabinoid receptors
WO2005037199A2 (en) 2003-10-10 2005-04-28 Bristol-Myers Squibb Company Pyrazole derivatives as cannabinoid receptor modulators
EP1763382A1 (en) * 2004-04-22 2007-03-21 L'oreal 2-oxy-acetamide compound, the uses thereof and compositions for stimulating or inducing the growth, and/or retarding the loss, of keratin fibres
FR2869224B1 (en) * 2004-04-22 2006-06-09 Oreal 2-OXY-ACETAMIDE COMPOUND, USES THEREOF AND COMPOSITIONS FOR STIMULATING OR INDUCING THE PUSH OF KERATIN FIBERS AND / OR BRAKING THEIR FALL
AU2006236387A1 (en) * 2005-04-18 2006-10-26 Neurogen Corporation Subtituted heteroaryl CB1 antagonists
AU2009218115B2 (en) 2008-02-28 2013-05-30 Nippon Shinyaku Co., Ltd. Fibrosis inhibitor
ES2875944T3 (en) 2008-03-18 2021-11-11 Arena Pharm Inc Prostacyclin (PG12) receptor modulators useful for treating prostacyclin-related disorders
WO2009154246A1 (en) * 2008-06-19 2009-12-23 日本新薬株式会社 Therapeutic agent for erectile dysfunction
ES2611483T3 (en) * 2008-06-23 2017-05-09 Nippon Shinyaku Co., Ltd. Therapeutic agent for inflammatory bowel disease
WO2009157397A1 (en) * 2008-06-23 2009-12-30 日本新薬株式会社 Therapeutic agent for intestinal tract injury accompanying administration of a non-steroid anti-inflammatory agent
EP2292231B1 (en) 2008-06-23 2015-10-21 Nippon Shinyaku Co., Ltd. Therapeutic agent for spinal canal stenosis
CA2730599C (en) * 2008-07-23 2016-09-13 Toray Industries, Inc. Therapeutic agent for chronic renal failure
BRPI0917661B8 (en) * 2008-08-13 2021-05-25 Actelion Pharmaceuticals Ltd product, pharmaceutical composition and use of the combination of macitentan with a compound that is endowed with prostacyclin receptor agonist properties
HUE048467T2 (en) 2009-06-26 2020-07-28 Nippon Shinyaku Co Ltd Crystals
WO2011024874A1 (en) * 2009-08-26 2011-03-03 日本新薬株式会社 Base addition salts
KR101701943B1 (en) 2009-11-13 2017-02-02 도레이 카부시키가이샤 Therapeutic or prophylactic agent for diabetes
PL2531492T3 (en) 2010-02-05 2016-10-31 1,2,4-triazine-4-amine derivatives
BR112013000946B1 (en) 2010-07-14 2020-09-08 Novartis Ag IP RECEPTOR AGONIST HETEROCYCLIC COMPOUNDS, THEIR USES, PHARMACEUTICAL COMPOSITION AND COMBINATION
EP2802589B1 (en) 2012-01-13 2016-01-06 Novartis AG Fused pyrroles as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
US9181186B2 (en) 2012-02-13 2015-11-10 Takeda Pharmaceutical Company Limited Aromatic ring compound
WO2013122028A1 (en) 2012-02-13 2013-08-22 武田薬品工業株式会社 Aromatic ring compound
JP6400479B2 (en) 2012-10-29 2018-10-03 株式会社カルディオ Lung disease specific therapeutic agent
WO2014125413A1 (en) 2013-02-13 2014-08-21 Novartis Ag Ip receptor agonist heterocyclic compounds
JP6449166B2 (en) 2013-10-15 2019-01-09 小野薬品工業株式会社 Drug-eluting stent graft
CN103588598B (en) * 2013-11-20 2015-06-17 苏州大学 Method for preparing 2-olefine aldehyde derivatives
CN104829465B (en) * 2015-02-13 2018-04-27 普济生物科技（台州）有限公司 A kind of preparation method of 4- isopropylaminos-n-butyl alcohol
CN106279047B (en) * 2015-05-13 2019-05-03 普济生物科技（台州）有限公司 A kind of preparation method of prostacyclin receptor agonist
WO2016193994A1 (en) 2015-05-29 2016-12-08 Megafine Pharma (P) Ltd. Amorphous selexipag and process for preparation thereof
CN106467496B (en) * 2015-08-14 2020-12-08 苏州国匡医药科技有限公司 Preparation method of 4- [ (5, 6-diphenyl piperazine-2-yl) (isopropyl) amino ] -1-butanol
EP3344607B1 (en) 2015-09-03 2019-11-06 Teva Pharmaceuticals International GmbH Solid state forms of selexipag
WO2017042731A1 (en) 2015-09-10 2017-03-16 Lupin Limited Amorphous form of selexipag and solid dispersion thereof
WO2017042828A2 (en) 2015-09-10 2017-03-16 Megafine Pharma (P) Ltd. Process for the preparation of selexipag and intermediates thereof
WO2017060827A1 (en) 2015-10-07 2017-04-13 Lupin Limited An imrpoved process for the preparation of selexipag or its pharmaceutically acceptable salts
AU2016366073B2 (en) 2015-12-02 2021-08-26 Nippon Shinyaku Co., Ltd. Pharmaceutical composition containing 2-{4-[N-(5,6- diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N- (methylsulfonyl)acetamide
WO2017109772A1 (en) * 2015-12-20 2017-06-29 Mapi Pharma Ltd. Amorphous form of selexipag
US11512042B2 (en) 2015-12-23 2022-11-29 Commonwealth Scientific And Industrial Research Organisation Enamine compounds for absorbance of electromagnetic energy
EP3192502A1 (en) 2016-01-15 2017-07-19 Sandoz Ag Pharmaceutical composition of selexipag
EP3436439B1 (en) * 2016-04-01 2022-02-16 Honour (R&D) Process for the preparation of diphenylpyrazine derivatives
CN107286104A (en) * 2016-04-12 2017-10-24 常州方楠医药技术有限公司 A kind of Sai Lexipa and pharmaceutic adjuvant solid dispersions and preparation method thereof
CN105949135A (en) * 2016-05-10 2016-09-21 湖南欧亚生物有限公司 Synthetic method of selexipag
CA3029960A1 (en) * 2016-07-05 2018-01-11 Maithri Drugs Private Limited Novel process for the preparation of 2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-n-(methylsulfonyl)acetamide and novel polymorphs thereof
WO2018015974A1 (en) 2016-07-20 2018-01-25 Mylan Laboratories Limited Polymorphic forms and amorphous solid dispersion of selexipag
WO2018015975A1 (en) * 2016-07-22 2018-01-25 Sun Pharmaceutical Industries Limited Amorphous solid dispersion of selexipag
WO2018022704A1 (en) 2016-07-26 2018-02-01 Teva Pharmaceuticals International Gmbh Crystalline form vi of selexipag
BR112018076800A2 (en) 2016-07-29 2019-04-02 Toray Industries, Inc. guanidine derivative, medicament, protein 1 inhibitor of mucosal-associated lymphoid tissue lymphoma translocation, and therapeutic or prophylactic agent.
WO2018019296A1 (en) * 2016-07-29 2018-02-01 成都苑东生物制药股份有限公司 Aminopyrazine compound, salt, or isomer, preparation method therefor, and application thereof
CN106316967B (en) * 2016-08-19 2019-02-05 上海艾康睿医药科技有限公司 The preparation method of West pa lattice intermediate and West pa lattice
WO2018078383A1 (en) 2016-10-27 2018-05-03 Cipla Limited Pharmaceutical composition comprising amorphous selexipag
AU2017378409A1 (en) 2016-12-14 2019-07-04 Respira Therapeutics, Inc. Methods and compositions for treatment of pulmonary hypertension and other lung disorders
EP3977985B1 (en) 2017-03-01 2023-09-06 Arena Pharmaceuticals, Inc. Compositions comprising pgi2-receptor agonists and processes for the preparation thereof
JOP20190204A1 (en) 2017-03-08 2019-09-05 Actelion Pharmaceuticals Ltd Pharmaceutical composition comprising selexipag
CN107365275B (en) * 2017-06-14 2020-07-03 杭州华东医药集团新药研究院有限公司 High purity celecoxib
RU2020106540A (en) 2017-07-27 2021-08-27 Аллерган, Инк. PROSTACYCLINE RECEPTOR AGONISTS TO REDUCE FAT IN THE BODY
TWI801421B (en) * 2017-09-28 2023-05-11 日商日本新藥股份有限公司 Crystals
AU2018369664A1 (en) * 2017-11-16 2020-05-21 Nippon Shinyaku Co., Ltd. Controlled release formulation
US10407396B2 (en) * 2017-11-16 2019-09-10 Apotex Inc. Crystalline form of selexipag
EP3750879A1 (en) * 2018-02-07 2020-12-16 Medshine Discovery Inc. Prostacyclin receptor agonist
CN112055591A (en) 2018-02-21 2020-12-08 日本新药株式会社 Granular composition, method for producing granular composition, and method for improving elution property of granular composition
CN108558653A (en) * 2018-05-14 2018-09-21 湖南华腾制药有限公司 The preparation method of Sai Lexipa intermediates and Sai Lexipa
CN108774183A (en) * 2018-08-03 2018-11-09 成都苑东生物制药股份有限公司 A kind of preparation method of ethylene glycol compounds
CN108863955B (en) * 2018-08-03 2021-08-13 成都苑东生物制药股份有限公司 Diphenyl pyrazine compound or pharmaceutically acceptable salt and isomer thereof, and preparation method and application thereof
CN109125325B (en) * 2018-09-25 2021-05-25 中国人民解放军总医院 Medical application of prostacyclin receptor agonist
JP2022532076A (en) 2019-05-06 2022-07-13 アクテリオン ファーマシューティカルズ リミテッド Treatment of sarcoidosis-related pulmonary hypertension
JP2022533394A (en) 2019-05-21 2022-07-22 アクテリオン ファーマシューティカルズ リミテッド How to transition patients being treated for pulmonary arterial hypertension to selexipag
EP3982967A1 (en) 2019-06-11 2022-04-20 Actelion Pharmaceuticals Ltd. Methods for treating pulmonary arterial hypertension
PH12022550380A1 (en) * 2019-08-19 2023-03-13 Nippon Shinyaku Co Ltd Salt
IL292354A (en) 2019-10-23 2022-06-01 Actelion Pharmaceuticals Ltd A pharmaceutical preparation containing Selexifag
MX2022006403A (en) 2019-11-29 2022-08-25 Actelion Pharmaceuticals Ltd Methods of treating pulmonary arterial hypertension.
US11969424B2 (en) 2019-12-16 2024-04-30 Tenax Therapeutics, Inc. Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF)
US20230113077A1 (en) 2020-01-31 2023-04-13 Actelion Pharmaceuticals Ltd Controlled release selexipag composition
WO2021156227A1 (en) 2020-02-03 2021-08-12 Actelion Pharmaceuticals Ltd Methods of treating and assessing pulmonary arterial hypertension with selexipag
WO2022106621A1 (en) 2020-11-20 2022-05-27 Actelion Pharmaceuticals Ltd Selexipag for use via intracolonic administration
TW202241425A (en) 2021-01-29 2022-11-01 瑞士商艾克泰聯製藥有限公司 Process for manufacturing a diphenylpyrazine derivative
TW202239408A (en) 2021-01-29 2022-10-16 瑞士商艾克泰聯製藥有限公司 Pharmaceutical composition comprising a diphenylpyrazine derivative
CN117157075A (en) 2021-03-31 2023-12-01 日本新药株式会社 Remedies for gait disorder
JP7010404B1 (en) 2021-03-31 2022-02-10 日本新薬株式会社 Gait disorder treatment agent
WO2022238375A1 (en) 2021-05-11 2022-11-17 Actelion Pharmaceuticals Ltd Methods of treating pulmonary hypertension
CN118206499A (en) * 2021-11-29 2024-06-18 郑州大学 A 2,3,5-trisubstituted pyrazine compound and its preparation method and application
EP4456897A1 (en) 2021-12-31 2024-11-06 Tenax Therapeutics, Inc. Oral formulations of levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction
WO2023131608A1 (en) 2022-01-04 2023-07-13 Actelion Pharmaceuticals Ltd Controlled release compositions
WO2023158634A1 (en) 2022-02-15 2023-08-24 United Therapeutics Corporation Crystalline prostacyclin (ip) receptor agonist and uses thereof
WO2023214059A1 (en) 2022-05-06 2023-11-09 Actelion Pharmaceuticals Ltd Diphenylpyrazine compounds as prodrugs
WO2024017964A1 (en) 2022-07-20 2024-01-25 Actelion Pharmaceuticals Ltd Injectable pharmaceutical composition comprising a diphenylpyrazine derivative
WO2024131672A1 (en) * 2022-12-20 2024-06-27 长风药业股份有限公司 Diphenyl pyrazine derivative, preparation method therefor, and use thereof
WO2024133620A1 (en) 2022-12-22 2024-06-27 Actelion Pharmaceuticals Ltd In vitro dissolution test
CN116143704A (en) * 2023-02-27 2023-05-23 广州楷石生物科技有限公司 Nitric Oxide Donor Drugs of In vivo Metabolites of Selexipag
TW202444370A (en) 2023-03-23 2024-11-16 瑞士商艾克泰聯製藥有限公司 Pharmaceutical composition comprising a diphenylpyrazine derivative
KR20250008015A (en) 2023-07-06 2025-01-14 재단법인대구경북과학기술원 Pharmaceutical composition for prevention or treatment of neurodegenerative diseases comprising selexipag
CN118619893A (en) * 2023-12-27 2024-09-10 石家庄四药有限公司 PGI2 receptor agonist compounds, pharmaceutical compositions and applications
CN118598820A (en) * 2024-02-06 2024-09-06 石家庄四药有限公司 A diphenyltriazine compound and its preparation method and application

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1105463B (en) 1977-05-17 1985-11-04 Diamond Shamrock Corp 1,2,4-REPLACED TRIAZINES AND COMPOSITIONS CONTAINING THEM EQUIPPED WITH ANTI-INFLAMMATORY PHARMACOLOGICAL ANALGESIC ANTI-PYRETIC HYPOTHENSIVE ANALGESICS AND CENTRAL NERVOUS SYSTEM
US4513135A (en) * 1982-03-05 1985-04-23 Eli Lilly And Company Diaryl-pyrazine derivatives affecting GABA binding
FR2665159B1 (en) 1990-07-24 1992-11-13 Rhone Poulenc Sante NEW PYRIDINE AND QUINOLEIN DERIVATIVES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
WO1992002513A1 (en) 1990-08-06 1992-02-20 Fujisawa Pharmaceutical Co., Ltd. Heterocyclic compounds
US5219510A (en) * 1990-09-26 1993-06-15 Eastman Kodak Company Method of manufacture of cellulose ester film
JP3169413B2 (en) * 1992-01-31 2001-05-28 エーザイ株式会社 Imidazole derivatives
JPH0733752A (en) * 1993-07-16 1995-02-03 Sankyo Co Ltd Diphenylpyrazine derivative and herbicide
AUPP003297A0 (en) * 1997-10-27 1997-11-20 Fujisawa Pharmaceutical Co., Ltd. 4,5-diaryloxazole compounds
AUPQ253199A0 (en) * 1999-08-30 1999-09-23 Fujisawa Pharmaceutical Co., Ltd. Non-prostanoid prostaglandin I2-agonist

Also Published As

Publication number Publication date
CA2445344A1 (en) 2002-11-07
EP1400518B1 (en) 2007-01-17
BE2016C051I2 (en) 2021-07-19
CN1301973C (en) 2007-02-28
RU2003134190A (en) 2005-06-10
RU2283835C2 (en) 2006-09-20
BR0209249A (en) 2004-06-08
DK1400518T3 (en) 2007-03-26
TWI316055B (en) 2009-10-21
JP4479152B2 (en) 2010-06-09
BRPI0209249B8 (en) 2021-05-25
ES2276931T3 (en) 2007-07-01
BRPI0209249B1 (en) 2016-04-26
NL300836I2 (en) 2016-11-16
FR16C0042I1 (en) 2016-12-09
DE60217674T2 (en) 2007-10-11
LU93266I2 (en) 2016-12-19
DE60217674D1 (en) 2007-03-08
KR20040015174A (en) 2004-02-18
MXPA03009800A (en) 2004-01-29
WO2002088084A1 (en) 2002-11-07
US7205302B2 (en) 2007-04-17
EP1400518A4 (en) 2005-04-20
PT1400518E (en) 2007-03-30
CN1516690A (en) 2004-07-28
KR100921760B1 (en) 2009-10-15
JPWO2002088084A1 (en) 2004-09-09
EP1400518A1 (en) 2004-03-24
RU2283835C3 (en) 2021-02-15
US20040102436A1 (en) 2004-05-27
CA2445344C (en) 2011-07-26

Similar Documents

Publication Publication Date Title
FR16C0042I2 (en) DERIVATIVES OF HETEROCYCLIC COMPOUNDS AND DRUGS
EE200200357A (en) Pharmaceutical compositions providing increased concentrations of the drug substance
PT1221918E (en) ADMINISTRATION OF SUB-TENON DRUGS
EE200200349A (en) Means of administration of drugs having antiprogestin properties
FR2847253B1 (en) NOVEL DERIVATIVES OF PYRIDAZINONES AS MEDICAMENTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM
IL160714A0 (en) Heterocyclic substituted 2-(4-phenoxy) pyridine derivatives and pharmaceutical compositions containing the same
NO20042842L (en) Pharmaceutical formulations of platinum derivative
AU2002331391A1 (en) N-monoacylated derivatives of o-phenylenediamines, their six membered heterocyclic analogues and their use as pharmaceutical agents
LTC1345910I2 (en) CHINAZOLIDINE DERIVATIVES, MEDICINAL PRODUCTS CONTAINING THOSE COMPOUNDS, THEIR USES AND METHOD OF THEIR PREPARATION
NO20012248L (en) Pharmaceutical preparation of moxifloxacin
NO20000225D0 (en) Retarded drug formulations containing a combination of an opioid and an agonist
NO20013945D0 (en) Preparation of isoflavone derivatives
DE60201859D1 (en) Pharmaceutical use of N-carbamoylazole derivatives
BRPI0209720A2 (en) dosage and packaging of controlled release medication
NO20020531D0 (en) Beta-carbolin drug products
IL157740A0 (en) Heterocyclic derivatives and pharmaceutical compositions containing the same
NO20022021D0 (en) Indeno-, naphtho- and benzocyclohepta-dihydrotiazole derivatives, the preparation of the same and their use as anorexic drugs
IL161854A0 (en) Heterocyclic derivatives of glycinamide and their medical use
PL367676A1 (en) Novel heterocyclic derivatives and medicinal use thereof
AU2002308891A1 (en) Novel heterocyclic derivatives and medicinal use thereof
IL159085A0 (en) Heterocyclic derivatives and pharmaceutical compositions containing the same
ATE362915T1 (en) HETEROCYCLIC DERIVATIVES AND DRUGS
DE60139306D1 (en) N-DEACETYLTHIOCOLCHIN DERIVATIVES AND MEDICAMENTS CONTAINING THEREOF
PT1178984E (en) DERIVATIVES OF 1-TRIFLUOROMETHYL-4-HYDROXY-7-PIPERIDINYLAMIMOME
HUP0204560A3 (en) Heterocyclic amide derivatives and pharmaceutical compositions containing them and their use